Get a Guide to Pharmaceutical Outsourcing in China

DUBLIN, Ireland--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/reports/c86346) has announced the
addition of "Guide to Pharmaceutical Outsourcing in China: A Handbook
for Pharmaceutical and Biotechnology Companies Planning to Outsource
to China" to their offering.

As China has become one of the hottest areas for pharmaceutical
and biopharmaceutical outsourcing, there is an urgent need for the
Western pharma and biotech companies, in particular those small-sized
ones who do not have sufficient internal resources to manage all steps
of the outsourcing process, to have a complete collection of the
information with regards to the current situation and service
capabilities of the Chinese pharmaceutical outsourcing service
providers. This guide is thus prepared to address these issues.

It provides answers to such questions as:

-- Whether is it the right time to go to China for outsourcing?

-- Who are those Chinese service providers?

-- What can they do?

-- How good is each of these individual Chinese CROs?

-- Where are they located?

-- How to approach them?

-- How to ensure my outsourcing effort in China will be
successful?

Besides, it also provides a step-by-step procedure for conducting
pharmaceutical outsourcing in China. The Guide could also serve as a
useful reference book for those executives in the pharmaceutical and
biotechnology industries as well as in the financial investment
industry who wish to have a complete understanding of what is really
going on in the Chinese pharmaceutical industry and how this industry
will develop in the near future.

Guide to Pharmaceutical Outsourcing in China - A Handbook for
Pharmaceutical and Biotechnology Companies Planning to Outsource to
China is concentrated on description of the current service
capabilities of Chinese CROs and the step-by-step procedures of how to
conduct and effectively manage the outsourcing activities in China,
the two urgent issues that at present need to be addressed for
pharmaceutical and biotech companies that either have potential
interests or are in planning to outsource to China.

The main features of the Guide include:

-- A complete and detailed analysis of the current service
capabilities of Chinese CROs in each outsourcing area and the
strategies of how to choose an ideal CRO that meets
outsourcing requirements.

-- An in-depth and objective evaluation of the potential risks
for outsourcing in China at present time and detailed
comparisons of the potential risks against apparent rewards.

-- A comprehensive list of suggestions of proper actions the
outsourcing companies, in particular the small-sized biotech
companies, should take in order to minimize the risks and
maximize the benefits from their outsourcing effort in China.

-- A complete collection of information of more than 60 Chinese
CROs that have capabilities to conduct contract research in
drug discovery and development. This information includes: the
service scope/capability of each Chinese CRO, comments on the
strengths of their service capability, the CRO company
founder's background and the year the CRO was founded, the
current number of technical employees (including the
approximate percentage of senior (Ph.D. level) scientists) in
each CRO company, as well as the complete contact information
including street and e-mail addresses, phone and fax numbers
as well as websites, etc.

-- Detailed comparisons between the Indian pharmaceutical
outsourcing service industry and the Chinese pharmaceutical
outsourcing service industry, including the strengths and
weakness of each country in each service area. Based on the
detailed analysis of the service features of each country, the
Guide further provides the suggestions to Western companies of
where to choose a suitable CRO for their outsourcing projects.

-- Valuable insights into the development trend of the world
pharmaceutical outsourcing industry, and, based on this trend,
a brave but reasonable prediction of the future development
trend of the Chinese pharmaceutical outsourcing service
industry in the next 5 to 10 years.

Companies Mentioned:

-- AbMax Biotechnology Co. Ltd

-- AcceleDev Chemical, Co. LLC

-- AllyChem, Ltd

-- Alputon, Inc

-- AstaTech, Inc

-- Asymchem Laboratories, Inc

-- Beijing Honghui Meditech

-- Beijing Joinn Pharmaceutical Center

-- Beijing Pharma Sciences

-- Beijing WisdomChem Co. Ltd

-- BioDuro

-- Bridge Pharmaceuticals

-- Charles River Laboratories

-- ChemExplorer

-- ChemiK Co. Ltd

-- Chemizon

-- ChemPacific Corporation

-- ChemPartner

-- ChengYi Pharmaceuticals Co

-- Chimica Laboratories

-- China Gateway Pharma Products, Ltd

-- Chiral Quest, Inc

-- CrimsonPharma

-- Crown Biosciences, Inc

-- Daxian Chemical Institute, Ltd

-- Ennova MedChem Group, Inc

-- Excel Pharma Studies

-- Fountain Medical Development, Ltd

-- FuXin Hengton Fluorine Chemicals Co. Ltd

-- HD Biosciences Co. Ltd

-- Huaxipharm Co. Ltd

-- Jiangsu Zhongdan Drug Research Co. Ltd

-- Laviana Corporation

-- Medicilon

-- Nanjing Chemzam Pharmtech Co. Ltd

-- ONICHEM

-- Paramax International, Inc

-- Pharmabridge, Inc

-- Pharmaron

-- Porton Corporation

-- Radiant Pharma & Tech Co., Ltd

-- ScinoPharm Kunshan

-- Shanghai LeadChem Co. Ltd

-- Shanghai SINCH Pharmaceuticals Tech. Co. Ltd

-- Shanghai SynCores Technologies, Inc

-- Sinova, Inc

-- StarVax, Inc

-- Sundia Meditech Co. Ltd

-- SynChem, Inc

-- Synergetica, Inc

-- Synergy PharmaTech Co. Ltd

-- Tyger Scientific, Inc

-- United PharmaTech

-- Vivo Development, Ltd

-- WatsonChem

-- Wilmington PharmaTech

-- WuXi PharmaTech

-- 2Y-CHEM, Ltd

-- Yield Pharma

-- Zannan Pharma

-- Zhejiang Qiming Pharmaceuticals Co. Ltd

For more information, visit
here

Research and Markets
Laura Wood
Senior Manager
Fax: +353 1 4100 980
press@researchandmarkets.com

Copyright Business Wire 2008